Amarillo Biosciences Pages on BioPortfolio:

BioPortfolio Biotechnology BioNews : live article
Amarillo Biosciences IND Application Passes FDA Review ... Amarillo Biosciences has privately placed 1200000 shares of restricted stock for $660000 with a ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=h...

BioPortfolio - Hayashibara Biochemical Labs
BioPortfolio - Hayashibara Biochemical Labs Amarillo Biosciences Announces Loan Agreement With Hayashibara ... Hayashibara Laboratories is, and continues to ...
http://www.bioportfolio.com/search/_Hayashibara_Biochemical_...

BioPortfolio Biotechnology BioNews : live article
Amarillo Biosciences Announces Phase II Study of Orally Administered ... Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=h...

BioPortfolio - Warts
Amarillo Biosciences, Inc., (ABI), is a biopharmaceutical company developing low -dose oral and topical interferon alpha. We are directing our research at ...
http://www.bioportfolio.com/indepth/Warts.html...

BioPortfolio's Warts News and Headlines
Amarillo Biosciences Announces Two Additional Clinical Sites for Phase 2 Study ... Amarillo Biosciences Issues Corporate Update on Influenza and Hepatitis C
...
http://www.bioportfolio.co.uk/Health_News/Warts.shtml...

BioPortfolio - Ambergen Inc. Revenue
ALZHEIMER'S COMMUNITY CARE, INC. ALZHEIMER'S DRUG DISCOVERY FOUNDATION · AMAR INTERNATIONAL, INC. AMARILLO BIOSCIENCES, INC. AMBERGEN, INC · AMBERGEN, INC.
...
http://www.bioportfolio.com/search/Ambergen_Inc._Revenue.htm...

BioPortfolio Biotechnology BioNews : live article
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=h...

BioPortfolio.com - BioWeb RIBASPHERE RIBAVIRIN cytopharm ...
AMAR - Amarillo Biosciences Inc - Oral Interferon Development Investor Relations :- Philippe Niemetz PAN Consultants, Ltd.- Tel: 800-477-7570 Tel: ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?DB=se...

BioPortfolio Biotechnology BioNews : live article
Amarillo Biosciences Announces Open Enrollment in Its Phase 2 Study of Orally ... Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=h...

Results from other life science and pharmaceutical sites:

BioSpace - Amarillo Biosciences News, Search Jobs, Events
Amarillo Biosciences Inc. 800 West 9th Avenue Amarillo Texas 79101-0000 U.S.A. Phone: 806-376-1741 Fax: 806-376-9301 ...
http://www.biospace.com/company_profile.aspx?CompanyId=1703...

Amarillo Biosciences Announces Loan Agreement With Hayashibara ...
Amarillo Biosciences is conducting a Phase III clinical trial using low dose oral interferon alpha for the treatment of Sjogren's syndrome. ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

BioMed Central | PDF | Interferon-a (Amarillo Biosciences).
Interferon-a (Amarillo Biosciences). DL Barnard Current Opinion in Investigational Drugs 2002 3:693-697. Access to the full text of this article
requires a ...
http://www.biomedcentral.com/content/pdf/cd-451241.pdf...

Hepatitis C: Amarillo Biosciences, Inc. and Biopharm Group ...
This agreement calls for the clinical co-development and marketing of Amarillo Biosciences' low dose orally administered interferon alpha (IFN alpha) in ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

Interferon-alpha. Amarillo Biosciences. [Curr Opin Investig Drugs ...
Amarillo Biosciences is developing low-dose oral interferon-alpha (IFNalpha; Veldona) as a potential treatment for primary Sjøgren's syndrome, ...
http://www.ncbi.nlm.nih.gov/pubmed/12090541...

Amarillo Biosciences Submits Investigational New Drug Application ...
AMARILLO, TX--(MARKET WIRE)--Jul 7, 2006 -- Amarillo Biosciences, Inc. (ABI) ( OTC BB:AMAR.OB - News) today announced that it submitted an Investigational ...
http://www.biospace.com/news_story.aspx?NewsEntityId=23614...

Japanese Regulatory Approval Granted for Oral Interferon Treatment ...
Amarillo Biosciences President and CEO Dr. Joseph Cummins Addressing Seminars in Japan Company to Receive Royalties and Expects to Form Strategic ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

CN Group and Texas Healthcare & Bioscience Institute Announce ...
CN Group and Texas Healthcare & Bioscience Institute Announce Final Agenda for 4th ... Systems (Dallas) - Presentation by Bob Kramer Amarillo Biosciences, ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright 1997-2008 - BioPortfolio Limited.